Venus Medtech (Hangzhou) (2500) Fundamentals 2026 — Revenue Analysis | SniperIQ

.22 on the HKSE. This SniperIQ fundamentals page covers Venus Medtech (Hangzhou)'s valuation, profitability (net margin -132.9%), revenue (¥307M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Venus Medtech (Hangzhou)'s market cap?

Venus Medtech (Hangzhou) (2500) has a market capitalization of approximately HK$538M, trading at HK

.22 on the HKSE. Market cap moves with the live share price.

What is Venus Medtech (Hangzhou)'s P/E ratio?

Venus Medtech (Hangzhou)'s trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Venus Medtech (Hangzhou)?

Venus Medtech (Hangzhou) runs a net profit margin of -132.9%, a gross margin of 69.0%, and an operating margin of -112.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Venus Medtech (Hangzhou) generate?

Venus Medtech (Hangzhou) reported revenue of ¥307M for fiscal year 2025, with net income of -¥408M and earnings per share (EPS) of -0.93. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Venus Medtech (Hangzhou) pay a dividend?

Venus Medtech (Hangzhou) does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Venus Medtech (Hangzhou) financially healthy?

Venus Medtech (Hangzhou) carries a debt-to-equity ratio of 0.12x and a current ratio of 2.77x, with a market beta of 1.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Venus Medtech (Hangzhou) a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Venus Medtech (Hangzhou) (2500) the key facts are: market cap HK$538M, revenue ¥307M, 52-week range 1.06-5.47. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.